Apply the Science Act

Bill: 117-s-3809
Sponsor: full_name: Sen. Braun, Mike [R-IN]
Introduced: 2022-03-10
Policy area: Health
Subjects: Cardiovascular and respiratory health

Centers for Disease Control and Prevention (CDC)

Congressional oversight

Department of Health and Human Services

Emergency medical services and trauma care

Government studies and investigations

Health promotion and preventive care

Immunology and vaccination

Infectious and parasitic diseases

Medical research

Medical tests and diagnostic methods
Latest action: action_date: 2022-03-10
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2022-03-10
action_desc: Introduced in Senate
text: <p><strong>Apply the Science Act</strong></p> <p>This bill requires the Government Accountability Office to study matters related to COVID-19 immunity, including variation in immunity resulting from prior infection, vaccination, or both.</p>

tv_txt: II 117th CONGRESS 2d Session S. 3809 IN THE SENATE OF THE UNITED STATES March 10 (legislative day, March 7), 2022 Mr. Braun (for himself and Mr. Marshall ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To require the Comptroller General of the United States to conduct a study relating to COVID–19 immunity resulting from a prior infection, vaccination, or both, and the COVID–19 pandemic.

1. Short title This Act may be cited as the Apply the Science Act . 2. GAO study on natural immunity in relation to the COVID–19 pandemic (a) Study Not later than 180 days after the date of enactment of this Act, the Comptroller General of the United States shall conduct a study to determine the following: (1) What is the current scientific understanding of the duration and effectiveness of COVID–19 immunity resulting from a prior infection, vaccination, or both, including any differences across population groups. (2) To what extent does the Centers for Disease Control and Prevention make available, to key stakeholders, the body of work it has assessed to inform its policy decisions related to COVID–19 infection-acquired and vaccine-induced immunity. (3) To what extent do select foreign countries take into account the scientific evidence pertaining to COVID–19 infection-acquired immunity when creating public health regulations or guidance. (4) To what extent can diagnostic tests that measure the immune response be better utilized in a comprehensive COVID–19 response, including in high-risk population groups, and barriers to current use of these diagnostic tests. (b) Report Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall submit to the appropriate committees of Congress a report on the determinations made pursuant to subsection (a).